# Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans

> **NCT01590277** · PHASE1 · COMPLETED · sponsor: **VA Office of Research and Development** · enrollment: 33 (actual)

## Conditions studied

- Active Ethanol and Active Iomazenil
- Active Ethanol and Placebo Iomazenil
- Placebo Ethanol and Active Iomazenil
- Placebo Ethanol and Placebo Iomazenil
- Alcohol Effect
- Driving Under the Influence
- Alcohol Impairment

## Interventions

- **DRUG:** Active Ethanol
- **DRUG:** Active Iomazenil
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01590277
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-14
- **Primary completion:** 2018-11-02
- **Final completion:** 2018-11-02
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01590277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01590277, "Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01590277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*